The Merck KGaA spinout has a tau-regulating medicine it claims could be an “ideal therapy” for Alzheimer’s. The pitch has intrigued both healthcare investors and pharma venture arms.
Agreement enhances Company’s intellectual property portfolio SARASOTA, FL, July 16, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: SILO) ...